文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

877例浸润性小叶癌患者的生殖系致病突变图谱及肿瘤学结局特征分析

Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma.

作者信息

Huynh Victoria D, Mouabbi Jason, Kuerer Henry M, Wanis Kerollos Nashat, Abdel-Salam Hiam M, Gutierrez Angelica M, Johnson Helen M, Lucci Anthony, Hunt Kelly K, Arun Banu K

机构信息

Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Ann Surg Oncol. 2025 May 2. doi: 10.1245/s10434-025-17366-x.


DOI:10.1245/s10434-025-17366-x
PMID:40314901
Abstract

PURPOSE: There is a paucity of literature on germline pathogenic variants (gPVs) in patients with invasive lobular carcinoma (ILC). This study characterizes the landscape and compares clinicopathologic variables and treatment outcomes between those with and without gPVs. METHODS: A prospectively maintained institutional database was used to identify all patients diagnosed with nonmetastatic ILC who had germline genetic testing. Clinicopathologic characteristics and time to recurrence, contralateral cancer, and death were compared for patients with and without gPVs. Conditional hazard ratios, computed by Cox proportional hazards models, described associations between clinicopathologic factors, including gPV status, and cancer events. RESULTS: Of 4398 patients with nonmetastatic ILC seen between 1989 and 2024, 1170 patients were evaluated by genetic counselors; 877 underwent genetic testing. 10% (83/877) had gPVs, of whom 87% (72/83) had gPVs in known breast cancer predisposition genes; 13% had gPVs in preliminary evidence genes or genes not previously known to be breast cancer associated. Patients with gPVs were more likely to be younger than 40 years, be premenopausal, have high grade and triple-negative receptor status, and undergo mastectomy compared with those without gPV (p < 0.01). At median follow-up of 80 months (interquartile range, IQR 38-135 years), there was no significant difference in the time to contralateral breast cancer, distant or local-regional recurrence, and survival among patients with and without gPVs. CONCLUSION: In this large single-institutional analysis, patients with ILC had a distinct landscape of gPVs in breast cancer and non-breast cancer predisposition genes. A significant proportion of patients with ILC have gPVs, and these findings have potentially actionable implications.

摘要

目的:关于浸润性小叶癌(ILC)患者种系致病性变异(gPVs)的文献较少。本研究描述了其情况,并比较了有和没有gPVs的患者的临床病理变量及治疗结果。 方法:使用一个前瞻性维护的机构数据库来确定所有接受种系基因检测的非转移性ILC患者。比较了有和没有gPVs的患者的临床病理特征以及复发时间、对侧乳腺癌和死亡情况。通过Cox比例风险模型计算的条件风险比描述了包括gPV状态在内的临床病理因素与癌症事件之间的关联。 结果:在1989年至2024年间就诊的4398例非转移性ILC患者中,1170例患者由遗传咨询师进行了评估;877例接受了基因检测。10%(83/877)有gPVs,其中87%(72/83)在已知的乳腺癌易感基因中有gPVs;13%在初步证据基因或先前未知与乳腺癌相关的基因中有gPVs。与没有gPVs的患者相比,有gPVs的患者更可能年龄小于40岁、处于绝经前、具有高级别和三阴性受体状态,并且接受乳房切除术(p<0.01)。在中位随访80个月(四分位间距,IQR 38 - 135年)时,有和没有gPVs的患者发生对侧乳腺癌、远处或局部区域复发以及生存时间没有显著差异。 结论:在这项大型单机构分析中,ILC患者在乳腺癌和非乳腺癌易感基因中具有独特的gPVs情况。相当一部分ILC患者有gPVs,这些发现具有潜在的可采取行动的意义。

相似文献

[1]
Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma.

Ann Surg Oncol. 2025-5-2

[2]
Prophylactic mastectomy for the prevention of breast cancer.

Cochrane Database Syst Rev. 2004-10-18

[3]
Risk-reducing mastectomy for the prevention of primary breast cancer.

Cochrane Database Syst Rev. 2018-4-5

[4]
Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population.

Breast Cancer Res. 2025-1-15

[5]
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Health Technol Assess. 2007-11

[6]
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast.

Breast Cancer. 2025-5-2

[7]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[8]
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.

Cochrane Database Syst Rev. 2018-8-24

[9]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[10]
WITHDRAWN: Multi-agent chemotherapy for early breast cancer.

Cochrane Database Syst Rev. 2008-10-8

本文引用的文献

[1]
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.

ESMO Open. 2024-10

[2]
Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation.

JAMA Netw Open. 2024-6-3

[3]
Germline CDH1 Variants and Lifetime Cancer Risk.

JAMA. 2024-9-3

[4]
CDH1 Genotype Exploration in Women With Hereditary Lobular Breast Cancer Phenotype.

JAMA Netw Open. 2024-4-1

[5]
Postpartum Breast Cancer and Survival in Women With Germline BRCA Pathogenic Variants.

JAMA Netw Open. 2024-4-1

[6]
Reporting on invasive lobular breast cancer in clinical trials: a systematic review.

NPJ Breast Cancer. 2024-3-20

[7]
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

J Clin Oncol. 2024-2-10

[8]
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Eur J Cancer. 2023-5

[9]
Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.

J Natl Cancer Inst. 2022-11-14

[10]
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.

Breast Cancer Res Treat. 2022-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索